Staidson Biopharmaceuticals Hits Day Low of CNY 23.40 Amid Price Pressure

Staidson (Beijing) Biopharmaceuticals Co., Ltd. experienced a notable decline today, with the stock hitting an intraday low of CNY 23.40, reflecting a decrease of 3.14% on July 13, 2026. This performance stands in contrast to the China Shanghai Composite, which fell by 2.06% on the same day. Over the past week, Staidson's stock has dropped by 7.5%, while its one-month performance shows a gain of 11.4%. However, the longer-term outlook reveals significant challenges, with a staggering 40.89% decline over the past year, compared to a 11.5% increase in the broader market index. Year-to-date, the stock is down 14.17%, further highlighting its underperformance relative to the market. Financial metrics indicate that Staidson is grappling with poor management efficiency, as evidenced by a return on capital employed (ROCE) of 0% and negative net worth. The company has reported losses for six consecutive quarters, with net sales declining at an annual rate of 15.81%. Despite a market capitalization of CNY 11,063 million, the stock's performance raises concerns about its sustainability and growth prospects in the competitive pharmaceuticals and biotechnology sector.